<p>根据 Marketbeat Ratings 的报告，Globus Medical, Inc.（纽约证券交易所代码：GMED - 获取免费报告）的股票获得了 14 家评级公司的平均推荐为 “适度买入”。六位投资分析师对该股票给予了持有推荐，八位分析师则对该公司发出了买入推荐。在过去一年中，发布报告的分析师对该股票的平均 12 个月目标价为 93.1111 美元。</p>
<p>获取 <strong>Globus Medical</strong> 的提醒：</p>
<p>几家研究公司对 GMED 发表了评论。Zacks Research 在 12 月 9 日的研究报告中将 Globus Medical 的评级从 “强力买入” 下调至 “持有”。加拿大皇家银行在 12 月 17 日的报告中将 Globus Medical 的目标价从 92.00 美元上调至 100.00 美元，并给予该公司 “跑赢大盘” 的评级。Truist Financial 在 11 月 18 日的研究报告中重申了 “买入” 评级，并将 Globus Medical 的目标价从 93.00 美元上调至 105.00 美元。华尔街 Zen 在 12 月 6 日的研究报告中将 Globus Medical 的评级从 “强力买入” 下调至 “买入”。最后，美国银行在 11 月 7 日的报告中将 Globus Medical 的评级从 “中性” 上调至 “买入”，并将该公司的目标价从 65.00 美元上调至 91.00 美元。</p>
<p><strong>查看我们最新的 GMED 股票分析</strong></p>
<h2>Globus Medical 股票表现</h2>
<p>纽约证券交易所：GMED 周五开盘价为 88.47 美元。该公司的 50 日移动平均线为 80.19 美元，200 日移动平均线为 65.75 美元。该公司的市值为 118.4 亿美元，市盈率为 28.54，PEG 比率为 1.63，贝塔值为 1.07。Globus Medical 的年内最低价为 51.79 美元，年内最高价为 94.93 美元。</p>
<p>Globus Medical（纽约证券交易所代码：GMED - 获取免费报告）最近在 11 月 6 日发布了季度财报。这家医疗设备公司报告的每股收益（EPS）为 1.18 美元，超出市场共识预期的 0.79 美元，超出幅度为 0.39 美元。该季度的营业收入为 7.6905 亿美元，而分析师预期为 7.3458 亿美元。Globus Medical 的股本回报率为 11.52%，净利润率为 15.30%。该公司的季度收入同比增长 22.9%。在去年同期，该公司每股收益为 0.83 美元。Globus Medical 已将其 2025 财年的指导目标设定为 3.750-3.85 美元每股。作为一个整体，股票研究分析师预测 Globus Medical 在当前财年将发布 3.44 美元的每股收益。</p>
<h2>Globus Medical 的内部交易</h2>
<p>在相关消息中，董事 David D. Davidar 在 11 月 12 日的交易中出售了 25,000 股公司的股票。该股票以 86.00 美元的平均价格出售，总价值为 2,150,000.00 美元。交易完成后，该董事持有 516,275 股公司的股票，价值约为 44,399,650 美元。这代表其持股比例减少了 4.62%。该交易已在向 SEC 提交的文件中披露，可以通过此超链接访问。此外，董事 Ann D. Rhoads 在 11 月 7 日的交易中出售了 8,000 股公司的股票。该股票以 81.00 美元的平均价格出售，总价值为 648,000.00 美元。交易完成后，该董事直接持有 17,384 股公司的股票，价值约为 1,408,104 美元。该交易使其持股比例减少了 31.52%。该销售的披露信息可在 SEC 文件中找到。内部人士在上个季度出售了价值 7,419,030 美元的 86,042 股公司股票。公司内部人士持有公司股票的 18.51%。</p>
<h2>机构投资者对 Globus Medical 的看法</h2>
<p>一些机构投资者最近增加或减少了对该股票的持股。Advisory Services Network LLC 在第三季度新购入了价值约 26,000 美元的 Globus Medical 股票。EverSource Wealth Advisors LLC 在第二季度将其在 Globus Medical 的持股增加了 74.3%。EverSource Wealth Advisors LLC 现在拥有 462 股该医疗设备公司的股票，价值 27,000 美元，此前在上个季度又购买了 197 股。Advisors Asset Management Inc.在第二季度新购入了价值约 28,000 美元的 Globus Medical 股票。First Horizon Corp 在第三季度新购入了价值约 31,000 美元的 Globus Medical 股票。最后，Parallel Advisors LLC 在第三季度将其在 Globus Medical 的持股增加了 45.1%。Parallel Advisors LLC 现在拥有 557 股该医疗设备公司的股票，价值 32,000 美元，此前在上个季度又购买了 173 股。机构投资者和对冲基金持有公司 95.16% 的股票。</p>
<h2>关于 Globus Medical</h2>
<p>（获取免费报告）</p>
<p>Globus Medical, Inc.（纽约证券交易所代码：GMED）是一家领先的医疗设备公司，专注于脊柱和骨科应用的肌肉骨骼解决方案。该公司于 2003 年由 David C. Paul 创立，总部位于宾夕法尼亚州 Audubon，开发、制造和销售旨在治疗脊柱疾病和促进骨愈合的植入设备和外科器械。其产品组合涵盖了用于微创和开放手术的解决方案，包括椎间融合设备、椎弓根螺钉系统和用于增强融合效果的生物制剂。</p>
<p>除了其核心脊柱业务外，Globus Medical 还扩展到机器人和导航系统，以支持手术室的精确性和效率。</p>
<h2>推荐故事</h2>
<ul>
<li>我们更看好的五只股票比 Globus Medical 更好</li>
<li>华尔街股票挑选者评选 2026 年第一只股票</li>
<li>[紧急！] SpaceX 即将上市！- IPO 前的行动</li>
<li>警报：在 2026 年 1 月之前抛售这五只股票！</li>
<li>华盛顿为战争做准备</li>
<li>距离崩盘一个月</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUdNRUQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUdNRUQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Globus Medical 吗？</h2>
<p>在考虑 Globus Medical 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前购买……而 Globus Medical 并不在名单上。</p>
<p>虽然 Globus Medical 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

Globus医疗

<p>Globus Medical, Inc.（纽约证券交易所代码：GMED）获得了 14 家券商的平均 “适度买入” 评级，12 个月目标价为 93.11 美元。分析师发布了 6 个持有和 8 个买入的建议。最近的变化包括 Zacks Research 将评级下调至 “持有”，加拿大皇家银行将目标价上调至 100 美元。该公司报告了强劲的季度收益，超出预期，每股收益为 1.18 美元，收入为 7.6905 亿美元。内部交易包括董事的重大股票出售</p>

<p>Shares of Globus Medical, Inc. (NYSE:GMED - Get Free Report) have earned an average recommendation of &#34;Moderate Buy&#34; from the fourteen ratings firms that are covering the stock, Marketbeat Ratings reports. Six investment analysts have rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $93.1111.</p>
<div class="lb-trans"><p>根据 Marketbeat Ratings 的报告，Globus Medical, Inc.（纽约证券交易所代码：GMED - 获取免费报告）的股票获得了 14 家评级公司的平均推荐为 “适度买入”。六位投资分析师对该股票给予了持有推荐，八位分析师则对该公司发出了买入推荐。在过去一年中，发布报告的分析师对该股票的平均 12 个月目标价为 93.1111 美元。</p>
</div><p>Get <strong>Globus Medical</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Globus Medical</strong> 的提醒：</p>
</div><p>Several research firms have commented on GMED. Zacks Research lowered Globus Medical from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research report on Tuesday, December 9th. Royal Bank Of Canada lifted their target price on shares of Globus Medical from $92.00 to $100.00 and gave the company an &#34;outperform&#34; rating in a report on Wednesday, December 17th. Truist Financial reiterated a &#34;buy&#34; rating and issued a $105.00 target price (up from $93.00) on shares of Globus Medical in a research note on Tuesday, November 18th. Wall Street Zen lowered shares of Globus Medical from a &#34;strong-buy&#34; rating to a &#34;buy&#34; rating in a research report on Saturday, December 6th. Finally, Bank of America raised shares of Globus Medical from a &#34;neutral&#34; rating to a &#34;buy&#34; rating and lifted their price objective for the company from $65.00 to $91.00 in a report on Friday, November 7th.</p>
<div class="lb-trans"><p>几家研究公司对 GMED 发表了评论。Zacks Research 在 12 月 9 日的研究报告中将 Globus Medical 的评级从 “强力买入” 下调至 “持有”。加拿大皇家银行在 12 月 17 日的报告中将 Globus Medical 的目标价从 92.00 美元上调至 100.00 美元，并给予该公司 “跑赢大盘” 的评级。Truist Financial 在 11 月 18 日的研究报告中重申了 “买入” 评级，并将 Globus Medical 的目标价从 93.00 美元上调至 105.00 美元。华尔街 Zen 在 12 月 6 日的研究报告中将 Globus Medical 的评级从 “强力买入” 下调至 “买入”。最后，美国银行在 11 月 7 日的报告中将 Globus Medical 的评级从 “中性” 上调至 “买入”，并将该公司的目标价从 65.00 美元上调至 91.00 美元。</p>
</div><p><strong>View Our Latest Stock Analysis on GMED</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 GMED 股票分析</strong></p>
</div><h2>Globus Medical Stock Performance</h2>
<div class="lb-trans"><h2>Globus Medical 股票表现</h2>
</div><p>NYSE:GMED opened at $88.47 on Friday. The firm's fifty day moving average is $80.19 and its two-hundred day moving average is $65.75. The firm has a market cap of $11.84 billion, a price-to-earnings ratio of 28.54, a PEG ratio of 1.63 and a beta of 1.07. Globus Medical has a one year low of $51.79 and a one year high of $94.93.</p>
<div class="lb-trans"><p>纽约证券交易所：GMED 周五开盘价为 88.47 美元。该公司的 50 日移动平均线为 80.19 美元，200 日移动平均线为 65.75 美元。该公司的市值为 118.4 亿美元，市盈率为 28.54，PEG 比率为 1.63，贝塔值为 1.07。Globus Medical 的年内最低价为 51.79 美元，年内最高价为 94.93 美元。</p>
</div><p>Globus Medical (NYSE:GMED - Get Free Report) last issued its quarterly earnings data on Thursday, November 6th. The medical device company reported $1.18 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.79 by $0.39. The business had revenue of $769.05 million during the quarter, compared to analysts' expectations of $734.58 million. Globus Medical had a return on equity of 11.52% and a net margin of 15.30%.The company's revenue for the quarter was up 22.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.83 EPS. Globus Medical has set its FY 2025 guidance at 3.750-3.85 EPS. As a group, equities research analysts predict that Globus Medical will post 3.44 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Globus Medical（纽约证券交易所代码：GMED - 获取免费报告）最近在 11 月 6 日发布了季度财报。这家医疗设备公司报告的每股收益（EPS）为 1.18 美元，超出市场共识预期的 0.79 美元，超出幅度为 0.39 美元。该季度的营业收入为 7.6905 亿美元，而分析师预期为 7.3458 亿美元。Globus Medical 的股本回报率为 11.52%，净利润率为 15.30%。该公司的季度收入同比增长 22.9%。在去年同期，该公司每股收益为 0.83 美元。Globus Medical 已将其 2025 财年的指导目标设定为 3.750-3.85 美元每股。作为一个整体，股票研究分析师预测 Globus Medical 在当前财年将发布 3.44 美元的每股收益。</p>
</div><h2>Insider Transactions at Globus Medical</h2>
<div class="lb-trans"><h2>Globus Medical 的内部交易</h2>
</div><p>In related news, Director David D. Davidar sold 25,000 shares of the company's stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $86.00, for a total value of $2,150,000.00. Following the completion of the transaction, the director owned 516,275 shares of the company's stock, valued at approximately $44,399,650. This represents a 4.62% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Ann D. Rhoads sold 8,000 shares of the firm's stock in a transaction that occurred on Friday, November 7th. The shares were sold at an average price of $81.00, for a total value of $648,000.00. Following the completion of the sale, the director directly owned 17,384 shares in the company, valued at approximately $1,408,104. The trade was a 31.52% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 86,042 shares of company stock worth $7,419,030 over the last quarter. Company insiders own 18.51% of the company's stock.</p>
<div class="lb-trans"><p>在相关消息中，董事 David D. Davidar 在 11 月 12 日的交易中出售了 25,000 股公司的股票。该股票以 86.00 美元的平均价格出售，总价值为 2,150,000.00 美元。交易完成后，该董事持有 516,275 股公司的股票，价值约为 44,399,650 美元。这代表其持股比例减少了 4.62%。该交易已在向 SEC 提交的文件中披露，可以通过此超链接访问。此外，董事 Ann D. Rhoads 在 11 月 7 日的交易中出售了 8,000 股公司的股票。该股票以 81.00 美元的平均价格出售，总价值为 648,000.00 美元。交易完成后，该董事直接持有 17,384 股公司的股票，价值约为 1,408,104 美元。该交易使其持股比例减少了 31.52%。该销售的披露信息可在 SEC 文件中找到。内部人士在上个季度出售了价值 7,419,030 美元的 86,042 股公司股票。公司内部人士持有公司股票的 18.51%。</p>
</div><h2>Institutional Investors Weigh In On Globus Medical</h2>
<div class="lb-trans"><h2>机构投资者对 Globus Medical 的看法</h2>
</div><p>A number of institutional investors have recently added to or reduced their stakes in the stock. Advisory Services Network LLC acquired a new stake in shares of Globus Medical in the third quarter valued at about $26,000. EverSource Wealth Advisors LLC raised its position in shares of Globus Medical by 74.3% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company's stock worth $27,000 after purchasing an additional 197 shares during the last quarter. Advisors Asset Management Inc. purchased a new position in Globus Medical in the 2nd quarter valued at about $28,000. First Horizon Corp acquired a new stake in Globus Medical in the 3rd quarter worth about $31,000. Finally, Parallel Advisors LLC increased its stake in Globus Medical by 45.1% during the 3rd quarter. Parallel Advisors LLC now owns 557 shares of the medical device company's stock worth $32,000 after buying an additional 173 shares in the last quarter. Institutional investors and hedge funds own 95.16% of the company's stock.</p>
<div class="lb-trans"><p>一些机构投资者最近增加或减少了对该股票的持股。Advisory Services Network LLC 在第三季度新购入了价值约 26,000 美元的 Globus Medical 股票。EverSource Wealth Advisors LLC 在第二季度将其在 Globus Medical 的持股增加了 74.3%。EverSource Wealth Advisors LLC 现在拥有 462 股该医疗设备公司的股票，价值 27,000 美元，此前在上个季度又购买了 197 股。Advisors Asset Management Inc.在第二季度新购入了价值约 28,000 美元的 Globus Medical 股票。First Horizon Corp 在第三季度新购入了价值约 31,000 美元的 Globus Medical 股票。最后，Parallel Advisors LLC 在第三季度将其在 Globus Medical 的持股增加了 45.1%。Parallel Advisors LLC 现在拥有 557 股该医疗设备公司的股票，价值 32,000 美元，此前在上个季度又购买了 173 股。机构投资者和对冲基金持有公司 95.16% 的股票。</p>
</div><h2>About Globus Medical</h2>
<div class="lb-trans"><h2>关于 Globus Medical</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Globus Medical, Inc NYSE: GMED is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.</p>
<div class="lb-trans"><p>Globus Medical, Inc.（纽约证券交易所代码：GMED）是一家领先的医疗设备公司，专注于脊柱和骨科应用的肌肉骨骼解决方案。该公司于 2003 年由 David C. Paul 创立，总部位于宾夕法尼亚州 Audubon，开发、制造和销售旨在治疗脊柱疾病和促进骨愈合的植入设备和外科器械。其产品组合涵盖了用于微创和开放手术的解决方案，包括椎间融合设备、椎弓根螺钉系统和用于增强融合效果的生物制剂。</p>
</div><p>In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.</p>
<div class="lb-trans"><p>除了其核心脊柱业务外，Globus Medical 还扩展到机器人和导航系统，以支持手术室的精确性和效率。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than Globus Medical</li>
<li>Wall Street Stockpicker Names #1 Stock of 2026</li>
<li>[URGENT!] SpaceX Going Public! – Pre-IPO Action</li>
<li>ALERT: Drop these 5 stocks before January 2026!</li>
<li>Washington prepares for war</li>
<li>A month before the crash</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Globus Medical 更好</li>
<li>华尔街股票挑选者评选 2026 年第一只股票</li>
<li>[紧急！] SpaceX 即将上市！- IPO 前的行动</li>
<li>警报：在 2026 年 1 月之前抛售这五只股票！</li>
<li>华盛顿为战争做准备</li>
<li>距离崩盘一个月</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUdNRUQ" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NYSE&amp;Symbol=GMED"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Globus Medical Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Globus Medical 吗？</h2>
</div><p>Before you consider Globus Medical, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Globus Medical 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Globus Medical wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前购买……而 Globus Medical 并不在名单上。</p>
</div><p>While Globus Medical currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Globus Medical 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Globus 医疗公司（NYSE:GMED）被券商给予平均评级为 “适度买入”